Resources from the same session
569 - Pembrolizumab in microsatellite instability high cancers: updated analysis of the phase 2 KEYNOTE-164 and KEYNOTE-158 studies
Presenter: Luis Diaz
Session: Proffered Paper – Immunotherapy of cancer
Resources:
Abstract
4445 - Association of tumor mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab in KEYNOTE-158
Presenter: Aurélien Marabelle
Session: Proffered Paper – Immunotherapy of cancer
Resources:
Abstract
Slides
Webcast
2365 - Durvalumab Activity in Previously Treated Patients Who Stopped Durvalumab without Disease Progression
Presenter: Siddharth Sheth
Session: Proffered Paper – Immunotherapy of cancer
Resources:
Abstract
Slides
Webcast
4019 - Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
Presenter: Susan Domchek
Session: Proffered Paper – Immunotherapy of cancer
Resources:
Abstract
Slides
Webcast
Proffered Paper – Immunotherapy of cancer - Invited Discussant 1174O and 1192O
Presenter: Francois Ghiringhelli
Session: Proffered Paper – Immunotherapy of cancer
Resources:
Slides
Webcast